Case Studies

Development of a whole CAR T cell specificity screen

Using cell lines provided by a clinical stage T cell therapy developer, Retrogenix has now developed an off-target profiling methodology which screens whole T cells for interactions against thousands of human plasma membrane protein targets to provide supporting data for pre-IND safety assessment. This case study describes the technology optimisation study and key results…

Read more

Compugen study identifies key TIGIT family immune checkpoint pair

Data presented at a recent conference showcased the utility of the Retrogenix platform in identifying a key immune checkpoint pairing within the TIGIT family. This case study provides further details of how PVRL2 was identified as a specific cell surface binding partner for PVRIG which has presented new opportunities for the development of cancer immunotherapy treatments including potential combination therapies with current immune checkpoint blockers…

Read more

Identifying human receptors mediating viral infection using cell microarray technology

This case study describes the discovery of the specific human cell surface receptor for the Hom-1 virus, a member of the caliciviridae family of viruses that infect a broad range of animal hosts and are associated with various chronic and acute illnesses. The Retrogenix technology was used to screen Hom-1 virus-like particles (VLP) against extensive arrays of human plasma membrane proteins over-expressed in human cells in order to identify a single, specific interacting protein…

Read more

Discovering anti-cancer biologics using phenotypic screening and Retrogenix’s target deconvolution technology

Scientists used 3-D phenotypic screening to select novel antibodies that were functional against primary tumour cells. The Retrogenix technology then identified the specific cell surface antigen targets of the most promising phenotypic molecules…

Read more

Using the Retrogenix technology to uncover immune checkpoint receptors

Many key immune checkpoint interactions are not yet fully characterised – hampering efforts to discover and develop new, targeted immuno-therapies. Results from Retrogenix’s plasma membrane protein array screening demonstrate an efficient method for rapidly identifying specific ligand-receptor binding in human cells.

Read more

Retrogenix identifies interactions mediated by post-translational modifications

Research aimed at understanding the mechanism by which one form of malaria specifically attacks the placenta in pregnant women has resulted in the discovery of a potential new therapy that could be effective in a wide range of cancers. Key interactions meditated via distinct chondroitin sulphate (CS) chains were detected by Retrogenix in the study showing the real advantage over traditional protein arrays which lack the physiological processing that enables proteins to be properly folded, glycosylated and multimerised prior to screening.

Read more

Retrogenix identifies cell surface receptor associated with malaria – Nature paper

Collaborating with the University of Copenhagen, Retrogenix was able to successfully identify a key cell surface receptor associated with a severe form of childhood malaria. This opens up exciting new possibilities for drug and vaccine treatments for the disease, which is currently responsible for around half a million deaths in Africa every year.

Read more

 Unravelling the molecular mechanisms of pulmonary arterial hypertension

Researchers from the University of Sheffield, UK, have furthered their understanding of the molecular mechanisms of a fatal lung condition by using the Retrogenix cell microarray technology to identify human cell surface receptors for osteoprotegerin (OPG) – a secreted glycoprotein that is elevated in patients with the disease. The study sheds light on the signalling mechanisms through which OPG induces proliferation of pulmonary arterial smooth muscle cells.

Read more

Pfizer
The University of Sheffield
Aveo Oncology - The Human Response
Theraclone Sciences
BioInvent
AstraZeneca
Bluebird Bio
The Center for Infectious Disease Research
Compugen Logo
The University of Copenhagen
Lund University
MedImmune
NIH - National Institutes of Health
The University of Pennsylvania
Scripps Florida - The Scripps Research Institute
Peptinnovate Ltd - Unlocking Nature's Potential
Retrogenix have been an excellent partner for us, and done high-quality studies. They have a collaborative approach and the flexibility to design studies to ensure the best possible outcomes.
Dr. David King, SVP Research, aTyr Pharma